Loading... Please wait... Loading... Please wait...
ESTIMATED
05/16/2024
05/16/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | -$0.10 | -$0.10 | -$0.10 |
| Q2 2024 | 3 | -$0.11 | -$0.06 | -$0.09 |
| Q3 2024 | 1 | -$0.10 | -$0.10 | -$0.10 |
| Q4 2024 | 0 | -$0.14 | -$0.14 | -$0.14 |
| Q1 2025 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2025 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2025 | 1 | -$0.14 | -$0.14 | -$0.14 |
| Q4 2025 | 1 | -$0.15 | -$0.15 | -$0.15 |
Silence Therapeutics plc last posted its earnings results on Thursday, May 16th, 2024. The company reported $-0.05 earnings per share for the quarter, topping analysts' consensus estimates of $-0.23 by $0.18. The company had revenue of 12.41 M for the quarter and had revenue of 25.38 M for the year. Silence Therapeutics plc has generated $-1 earnings per share over the last year ($-1.17 diluted earnings per share) and currently has a price-to-earnings ratio of -17.68. Silence Therapeutics plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 21st, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/30/2024 | Q1 2024 | -$0.04 | $5.06 M | $12.41 M | 03/13/2024 | Q4 2023 | -$0.25 | -$0.37 | -0.12 | $7.08 M | $2.10 M | 09/29/2023 | Q3 2023 | -$0.22 | $2.41 M | $2.80 M | 06/30/2023 | Q2 2023 | -$0.29 | $3.06 M | $9.10 M | 03/31/2023 | Q1 2023 | -$0.28 | $2.49 M | $11.37 M | 03/15/2023 | Q4 2022 | $0.45 | -$0.43 | -0.88 | $16.51 M | $4.77 M | 09/29/2022 | Q3 2022 | -$0.22 | $3.37 M | 06/29/2022 | Q2 2022 | -$0.40 | $3.64 M | 03/30/2022 | Q1 2022 | -$0.26 | $5.72 M | 03/17/2022 | Q4 2021 | -$0.62 | -$0.32 | 0.3 | $3.41 M | 09/29/2021 | Q3 2021 | -$0.33 | $3.16 M | 06/30/2021 | Q2 2021 | -$0.39 | $2.70 M | 03/31/2021 | Q1 2021 | -$0.29 | $3.14 M | 03/30/2021 | Q4 2020 | -$0.07 | $-842,000 | 09/29/2020 | Q3 2020 | -$0.33 | $1.99 M | 06/29/2020 | Q2 2020 | -$0.18 | $573,000 |
|---|
A. Silence Therapeutics plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 21st, 2024 based off last year's report dates.
A. In the previous quarter, Silence Therapeutics plc (NASDAQ:SLN) reported $-0.05 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.23 by $0.18.
A. The conference call for Silence Therapeutics plc's latest earnings report can be listened to online.
A. The conference call transcript for Silence Therapeutics plc's latest earnings report can be read online.
A. Silence Therapeutics plc (NASDAQ:SLN) has a recorded annual revenue of $25.38 M.
A. Silence Therapeutics plc (NASDAQ:SLN) has a recorded net income of $25.38 M. Silence Therapeutics plc has generated $-1.17 earnings per share over the last four quarters.
A. Silence Therapeutics plc (NASDAQ:SLN) has a price-to-earnings ratio of -17.68 and price/earnings-to-growth ratio is -2.48.
